Key result
Catheter ablation reverses elevations in 11 persistent AF-related plasma proteins at 12 months.
Why the study?
Current AF prediction models largely rely on electronic health records and do not capture key biological processes such as inflammation reflected in the plasma proteome. Identifying AF-associated plasma proteins may improve understanding of the inflammatory and other biological processes underlying AF pathophysiology.
Does catheter ablation alter longitudinal plasma proteome expression profiles at 12 months in patients with paroxysmal and persistent atrial fibrillation compared to non-AF controls?
Observational (n=30)
No
Does catheter ablation alter longitudinal plasma proteome expression profiles at 12 months in patients with paroxysmal and persistent atrial fibrillation compared to non-AF controls?
This exploratory study identifies 11 plasma proteins upregulated in persistent AF that partially normalize 12 months after catheter ablation, highlighting systemic molecular pathways in inflammation, metabolism, and cell-matrix adhesion that may serve as biomarkers for AF.
Answers are grounded in this paper and cite their sources.
Plasma proteins may enhance AF prediction beyond EHR variables; leaves open whether they improve clinical models or outcomes.
Background Proteins in human plasma serve as critical markers for predicting disease risk and guiding therapeutic development. Current prediction models for atrial fibrillation (AF) largely rely on electronic health records; however, the plasma proteome of patients with AF reflects key biological processes, including inflammation, that are not captured by clinical variables alone. Circulating inflammatory mediators contribute to electrical and structural remodelling in the atria, thereby sustaining the AF phenotype. Identification of plasma proteins associated with AF may therefore improve understanding of the inflammatory and other biological processes underlying AF pathophysiology. Objective In this study, we profiled the plasma proteome of patients with paroxysmal AF (pxAF), persistent AF (persAF), and non-AF controls using Olink assay technology. Methods Plasma samples from 30 individuals were analysed with the Olink Reveal panel. Differential expression analysis of normalised protein expression (NPX) values was performed between groups, with differentially expressed proteins (DEPs) defined by P < 0.05. Results We identified 87 DEPs in pxAF and 107 DEPs in persAF compared with controls. From these, we shortlisted 11 candidate proteins that were upregulated in persAF at baseline and showed reduced expression 12 months after catheter ablation. This subset of proteins is implicated in the regulation of inflammation (CCL23, CXCL10, IL33), metabolism (ALDH3A1, NDUFS6), cell-matrix adhesion (AFAP1L1, LGALS7, SPOCK1), and physiological signalling (NOS1, PROK1, PTH). Conclusion Collectively, these plasma proteins highlight systemic molecular mechanisms contributing to AF pathogenesis and represent potential AF-specific biomarkers warranting further investigation in larger clinical cohorts and mechanistic studies.
No takes yet. Share an insight, caveat, or question.
Yiu et al. (2026) conducted an observational in Atrial fibrillation (n=30). Catheter ablation and atrial fibrillation status (paroxysmal and persistent AF) vs. Non-AF controls (supraventricular tachycardias or atrial flutter) and pre-ablation baseline was evaluated on Differentially expressed plasma proteins (DEPs) at baseline and 12 months post-ablation using the Olink Reveal panel (p=<0.05). Plasma proteome profiling identified 87 differentially expressed proteins in paroxysmal AF and 107 in persistent AF vs controls, with 11 proteins upregulated in persistent AF decreasing 12 months post-ablation.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: